Sep 2026· Human Gene Therapy· pp.
10430342261487919
· 0 citations· 58 references
Medicine
TL;DR
A CD7-targeted rAAV vector featuring a nanobody-fused hybrid capsid derived from a rationally selected chimeric combination of AAV6 and AAV9 establishes an integrated capsid-genome design framework for targeting human T and NK cells, notoriously challenging immune cell populations for gene therapy, and provides a versatile platform readily adaptable to alternative surface markers and therapeutic payloads.
Abstract
Recombinant adeno-associated virus (rAAV) vectors are widely used for gene delivery but show limited efficiency in immune cells, including T lymphocytes and natural killer (NK) cells. To overcome this barrier, we have developed a CD7-targeted rAAV vector (CD7-AAV6/9) featuring a nanobody-fused hybrid capsid derived from a rationally selected chimeric combination of AAV6 and AAV9. CD7-AAV6/9 enables efficient and selective transduction of immortalized and primary human T and NK cells in vitro and in vivo in a humanized mouse model, achieves high production titers, and exhibits markedly reduced off-target transduction compared with wild-type serotypes. Incorporation of a human gene-derived intron into the vector genome to overcome host-mediated transcriptional repression enables robust transgene expression in human CD7+ T lymphocyte and NK cell populations. Together, our findings establish an integrated capsid-genome design framework for targeting human T and NK cells, notoriously challenging immune cell populations for gene therapy, and provide a versatile platform readily adaptable to alternative surface markers and therapeutic payloads.
A virus-like particle (VLP)-based toolkit that delivers diverse CRISPR editing modalities to human monocytes, macrophages and dendritic cells with high efficiency while preserving viability and innate immune responsiveness is presented.
Hyuncheol Jung, Pascal Devant, Carter Ching et al.· Nature Biotechnology· 0 citations
This study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.
Xin Wei, Xiang Li, Li-Xia Qi et al.· Frontiers in Immunology· 0 citations
A protocol that combines ribonucleoprotein-based CRISPR-Cas9 editing with retroviral transduction to enable efficient genetic manipulation of murine CD8 T cells is described and it is shown that T cells engineered via this protocol can be generated at sufficient scale for downstream in vitro assays and in vivo adoptive...
Nadine Tong, John Attanasio, Eric Fagerberg et al.· bioRxiv· 0 citations
Lentivirus (LV)-based manipulation of immune cells is a commonly used approach in cell therapies. However, the most frequently used Vesicular Stomatitis Virus Glycoprotein (VSV-G) pseudotyping approach is inefficient to support LV gene delivery of mouse immune cells due to the lack of an optimal entry receptor. Here, w...
Jian Li, Beatriz Goncalves, Gabrielle Melamed et al.· Frontiers in Immunology· 0 citations
This proof-of-concept study underlines the utility of the Env variant BaEV-TR for the establishment of stable pseudotype VPCLs and the utilization of HT1080 cells as an alternative to frequently used 293T host cells.
Angelina Hallik, Mona Pißarreck, Mats Jürgen Grummel et al.· Frontiers in Molecular Medic...· 0 citations
It is demonstrated that primary human T cells can produce retroviral-based enveloped delivery vehicles (EDVs) packaging functional Cas9 ribonucleoproteins and developed a miniaturized Moloney murine leukemia virus-based system that proved superior to existing architectures in this context and optimized both lentiviral...
J. Meixiong, Oleksandr Zginnyk, Lauren Chow et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.